


Supplemental Material: Appendix

Members of the 'AGO Breast Committee' in alphabetical order: U.-S. Albert, Frankfurt/M.; I. Bauerfeind, Landshut; J. Bischoff, Dessau; J.-U. Blohmer, Berlin; W. Budach, Düsseldorf; P. Dall, Lüneburg; I.J. Diel, Mannheim; P. Fasching, Erlangen; T. Fehm, Düsseldorf; N. Fersis, Bayreuth; M. Friedrich, Krefeld; B. Gerber, Rostock; V. Hanf, Fürth; N. Harbeck, Munich; J. Huober, Ulm; C. Jackisch, Offenbach; W. Janni, Ulm; H. Kreipe, Hannover; T. Kühn, Esslingen; S. Kümmel, Essen; C. Liedtke, Lübeck; S. Loibl, Neu-Isenburg; H.-J. Lück, Hannover; M. Lux, Erlangen; N. Maass, Kiel; G. von Minckwitz, Neu-Isenburg; V. Möbus, Frankfurt/M.; V. Müller, Hamburg; M. Müller-Schimpfle, Frankfurt/M.; C. Mundhenke, Kiel; U. Nitz, Mönchengladbach; Dr. M. Rezai, Düsseldorf; A. Rody, Lübeck; A. Scharl, Amberg; M. Schmidt, Mainz; R. Schmutzler, Cologne; A. Schneeweiss, Heidelberg; I. Schreer, Hamburg; F. Schütz, Heidelberg; P. Sinn, Heidelberg; C. Solbach, Frankfurt/M; E. Solomayer, Homburg; E. Stickeler, Aachen; M. Thill, Frankfurt/M.; C. Thomssen, Halle (Saale); M. Untch, Berlin; F. Wenz, Mannheim; I. Witzel, Hamburg

Suppl. table 1. AGO grades of recommendation

-
- ++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should be performed.
 - + This investigation or therapeutic intervention is of limited benefit for patients and can be performed.
 - +/- This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases. According to current knowledge, a general recommendation cannot be given.
 - This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed.
 - /- This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case.
-

Supplemental Material: Appendix



Prätherapeutische Abklärung suspekter Läsionen (BIRADS 4)

	Oxford / AGO LoE / GR
➤ Mammographie	1b A ++
➤ Vergrößerungsaufnahmen von Mikroverkalkungen	4 C ++
➤ Steigerung der Detektionsrate von G1/G2 DCIS durch digitale Mammographie (versus konventionell)	2b B +
➤ Stereotaktische Stanzbiopsie / Vakuumbiopsie (VAB)	2b B ++
➤ Präparateradiographie	2b B ++
➤ Setzen eines Markierungsclips in der Biopsieregion, wenn die Läsion komplett entfernt wurde	5 D ++
➤ MRT zur Festlegung der Ausdehnung	1b B +/-
➤ Klinische Untersuchung	5 D ++
➤ Feinnadelpunktion / duktale Lavage	5 D -
➤ Interdisziplinäre Tumorboard-Präsentation	5 D ++

Suppl. fig. 1. Pretherapeutic diagnostics of suspect lesions (BIRADS 4)




Risk Reducing Bilateral Mastectomy in Healthy Women (RRBM)

	Oxford / AGO LoE / GR
➤ RRBM reduces breast cancer incidence	1b A ++
➤ RRBM in deleterious BRCA1/2 mutation	2a B +*
➤ RRBM in high risk situation without BRCA 1/2 mutation (individual decision depending on personal-family history and mutational status – e.g. high and moderate risk genes, Hodgkin lymphoma)	3a C +/-*
➤ High risk and no BRCA counselling in specialized centre*	5 D --
➤ Non-directive counselling prior to RRBM	2b B ++*
➤ RRBM should be considered with other prophylactic surgical options incl. bilateral salpingoophorectomy (BSO)	2a A ++*
➤ Further need for education of physicians regarding possibilities and advantages of RRBM	1b A ++

*Counselling, risk prediction and follow-up in specialised centres recommended

Suppl. fig. 2. Risk-reducing bilateral mastectomy in healthy women.

Supplemental Material: Appendix



Radiotherapie (RT) anderer lokoregionärer Lymphabflussregionen (IMC)

	Oxford /AGO LoE / GR
Mammaria interna Lymphknotenregion (IMC)	
➤ pN0 prämenopausal, hohes Risiko*** ***zentraler oder medialer Sitz und G2-3 und ER/PgR-negativ	1b B +/-
➤ pN1a hohes Risiko* *zentraler oder medialer Sitz, und (G2-3 oder ER/PgR-negativ) *lateraler Sitz, prämenopausal und (G2-3 oder ER/PgR-negativ)	2a B +
➤ pN2a hohes Risiko** **G2-3 oder ER/PgR-negativ	2a B +
➤ pN1b-c, pN2c, pN3b	2a B +
➤ IMC-RT, bei kardialem Risiko oder bei Gabe von Trastuzumab Nach NACT/NAT (Indikation wie für PMRT) AGO ¹	2b A -- 2b B +/-
➤ Nach NACT/NAT bei cN+ (CNB/FNA) (Ind. wie PMRT) DEGRO ¹	2b A +

¹ Unterschiedliche Bewertung der publizierten Daten durch AGO und DEGRO

Suppl. fig. 3. Radiotherapy of other locoregional lymph drainage regions.

References

- 1 Oxford CEBM: Level of evidence, LoE, www.cebm.net
- 2 Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2017, www.ago-online.de
- 3 van Gemert WA, Lanting CI, Goldbohm RA, et al. The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. *Breast Cancer Res Treat.* 2015;152:155–162
- 4 Bao PP, Zhao GM, Shu XO, et al., Modifiable Lifestyle Factors and Triple-negative Breast Cancer Survival: A Population-based Prospective Study. *Epidemiology.* 201;26:909–916
- 5 Ärztekammer Westfalen-Lippe, Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Senologie, and Deutsches Konsortium für Erblichen Brust- und Eierstockkrebs. 2014. 'Checkliste zur Erfassung einer möglichen erblichen Belastung für Brust-und/oder

Supplemental Material: Appendix

- Eierstockkrebs (Mamma-Ca incl. DCIS)', http://www.konsortium-familiaerer-brustkrebs.de/fileadmin/downloads/FB-erbliche_Belastung_V2014-09-02.pdf, accessed March 5, 2017
- 6 Couch, F. J., S. N. Hart, P. Sharma, A. E. Toland, X. Wang, P. Miron, J. E. Olson, A. K. Godwin, V. S. Pankratz, C. Olswold, S. Slettedahl, E. Hallberg, L. Guidugli, J. I. Davila, M. W. Beckmann, W. Janni, B. Rack, A. B. Ekici, D. J. Slamon, I. Konstantopoulou, F. Fostira, A. Vratismos, G. Fountzilas, L. M. Pelttari, W. J. Tapper, L. Durcan, S. S. Cross, R. Pilarski, C. L. Shapiro, J. Klemp, S. Yao, J. Garber, A. Cox, H. Brauch, C. Ambrosone, H. Nevanlinna, D. Yannoukakos, S. L. Slager, C. M. Vachon, D. M. Eccles, and P. A. Fasching. 2015. 'Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer', *J Clin Oncol*, 33:304–11
- 7 Harrison, S. M., E. R. Riggs, D. R. Maglott, J. M. Lee, D. R. Azzariti, A. Niehaus, E. M. Ramos, C. L. Martin, M. J. Landrum, and H. L. Rehm. 2016. 'Using ClinVar as a Resource to Support Variant Interpretation', *Curr Protoc Hum Genet*, 89:8 16 1–8 16 23.
- 8 Landrum, M. J., J. M. Lee, M. Benson, G. Brown, C. Chao, S. Chitipiralla, B. Gu, J. Hart, D. Hoffman, J. Hoover, W. Jang, K. Katz, M. Ovetsky, G. Riley, A. Sethi, R. Tully, R. Villamarin-Salomon, W. Rubinstein, and D. R. Maglott. 2016. 'ClinVar: public archive of interpretations of clinically relevant variants', *Nucleic Acids Res*, 44:D862–8. National Institutes of Health of the United States of America. 2017. 'ClinVar Website', Accessed March 5, 2017
- 9 Fasching, P. A., S. Loibl, H. Eidtmann, H. Tesch, M. Untch, J. Hilfrich, C. Schem, M. Rezai, B. Gerber, S.D. Costa, J.U. Blohmer, T.N. Fehm, J. Huober, C. Liedtke, V. Müller, V. Nekljudova, K. Weber, B. Rack, M. Rübner, L. Wang, J.N. Ingle, R.M. Weinshilboum, G. von Minckwitz, and F. Couch. 2016. 'BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study', *Cancer Res*, 76:(4 Suppl):Abstract nr S5–06
- 10 Neidhardt G, Hauke J, Ramser J, Groß E, Gehrig A, Müller CR, Kahlert AK, Hackmann K, Honisch E, Niederacher D, Heilmann-Heimbach S, Franke A, Lieb W, Thiele H, Altmüller J, Nürnberg P, Klaschik K, Ernst C, Ditsch N, Jessen F, Ramirez A,

Supplemental Material: Appendix

- Wappenschmidt B, Engel C, Rhiem K, Meindl A, Schmutzler RK, Hahnen E. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. *JAMA Oncol.* 2016 Dec 29. doi: 10.1001/jamaoncol.2016.5592
- 11 von Minckwitz G., E. Hahnen, P. A. Fasching, J. Hauke, A. Schneeweiss, C. Salat, M. Rezai, J. U. Blohmer, D. M. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kummel, H. Eidtmann, S. Paepke, V. Nekljudova, S. Loibl, M. Untch, and R. K. Schmutzler. 2014. 'Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.', *J Clin Oncol*, 32:5s: (suppl; abstr 1005
- 12 Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW. Axillary treatment for operable primary breast cancer. *Cochrane Database Syst Rev.* 2017 Jan 4;1:CD004561. doi: 10.1002/14651858.CD004561.pub3
- 13 Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS et al Breast Cancer Screening for women at average risk. 2015 Guideline Update from the American Cancer Society. *JAMA* 2015;314:1599–1614
- 14 ECIBC 2016. European Commission on Breast Cancer: Statements. Abruf Evidencereport update 24/11/2016, Zugriff 20122016:<http://ecibc.jrc.ec.europa.eu/recommendations/list/3>
- 15 Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group: Breast-cancer screening—viewpoint of the IARC Working Group. *N Engl J Med* 2015;372:2353–2358
- 16 Nelson HD, et al. (2016a). Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med.* 2016 Feb 16;164(4):244–55
- 17 Nelson HD, et al. (2016b). Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med.* 2016 Feb 16;164(4):256–67
- 18 USPSTF 2016:US Preventive Services Task Force Final Recommendation Statement for

Supplemental Material: Appendix

mammographyScreening12.01.2016;<http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening> Zugriff 04112016

- 19 IACR Handbook 2016:Website for the IARC publications:
<http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016>
- 20 Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age
- 21 ACS 2015:Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines. Duke Evidence Synthesis Group. <http://www.cancer.org/acs/groups/content/documents/document/acspc-046315.pdf>. Zugriff am 11.August 2016
- 22 Skaane P, Bandos AI, Gullien R et al Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population –based screening program. Radiology 2013;267(1) 47–56
- 23 Skaane P, Bandos AI, Eben EB, Jebsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M, Hofwind S, Gullien R Two-view breast tomosynthesis screening with synthetically reconstructed projection images; Comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 2014;271(3)655–663
- 24 Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, Tuttobene P, Bricolo P, Fanto C, Valentini M, Montemezzi S, Houssami N Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. The Breast 2014;23:76–80
- 25 Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Barke DO, Greer LN, Miller DP, Conant EF Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014;311(24):2499–2507
- 26 Gilber FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY, Purushothaman H, Strudley C, Astley SM, Morrish O, Young KC, Duffy SW. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in

Supplemental Material: Appendix

- the UK NHS Breast Screening Programme - a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. *Health Technol Assess.* 2015 Jan;19(4):1–136
- 27 Hodgson R, Heywang-Köbrunner SH, Harvey SC, et al. Systematic review of 3D mammography for breast cancer screening. *Breast.* 2016 Jun;27:52–61. doi: 10.1016/j.breast.2016.01.002
- 28 Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14–05201-EF-3
- 29 Morel JC, Iqbal A, Wasan RK, Peacock C, Evans DR, Rahim R, Goligher J, Michell MJ. The accuracy of digital breast tomosynthesis compared with coned compression magnification mammography in the assessment of abnormalities found on mammography. *Clin Radiol.* 2014 Nov;69(11):1112–6
- 30 Cornford EJ, Turnbull AE, James JJ, Tsang R, Akram T, Burrell HC, Hamilton LJ, Tennant SL, Bagnall MJ, Puri S, Ball GR, Chen Y, Jones V. Accuracy of GE digital breast tomosynthesis vs supplementary mammographic views for diagnosis of screen-detected soft-tissue breast lesions. *Br J Radiol.* 2016;89(1058):20150735
- 31 American College of Radiology (ACR). D'Orsi CJ, Sickles EA, Mendelson EB et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. USA, Reston, VA: American College of Radiology; 2013
- 32 Müller-Schimpffle M. et al. BI-RADS die 5.–Eine Kurzmitteilung aus deutsch-/ österreichischer Sicht. *Fortschr Röntgenstr* 2016;188:346–352; *Geburtshilfe Frauenheilkd* 2016;76(05): 490–496; *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2016;13(03): 132–143
- 33 Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14–05201-EF-3

Supplemental Material: Appendix

- 34 Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. *Ann Intern Med.* 2015 Feb 3;162(3):157–66. doi: 10.7326/M14-0692
- 35 Tagliafico AS, Calabrese M, Mariscotti G, Durando M, Tosto S, Monetti F, Airaldi S, Bignotti B, Nori J, Bagni A, Signori A, Sormani MP, Houssami N. Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial. *J Clin Oncol* 2016;35:1882–1888
- 36 El Sharouni M, Postma EL, Menezes GLG, van den Bosch M, Pijnappel RM, Witkamp AJ, van der Pol CC, Verkooijen HM, van Diest PJ. High prevalence of MRI-detected contralateral and ipsilateral malignant findings in patients with invasive ductolobular breast cancer: Impact on surgical management. *Clin Breast Cancer.* 2016 Aug;16(4):269–75
- 37 Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. *Ann Surg.* 2013 Feb;257(2):249–55. doi: 10.1097/SLA.0b013e31827a8d17
- 38 Houssami N, Turner R, Macaskill P, Turnbull LW, McCready DR, Tuttle TM, Vapiwala N, Solin L J An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. *J Clin Oncol* 2014;32(5):392–401
- 39 Pianto JR, de Andrade RD, Chala LF, de Barros N, Mano MS, Melitto AS, Goncalves R, Soares Junior JM, Baracat EC, Filassi JR: MRI to Predict Nipple Involvement in Breast Cancer Patients. *AJR Am J Roentgenol.* 2016 May;206(5):1124–30
- 40 Luparia A, Mariscotti G, Durando M, Ciatto S, Bosco D, Campanino PP, Castellano I, Sapino A, Gandini G. Accuracy of tumour size assessment in the preoperative staging of breast cancer: comparison of digital mammography, tomosynthesis, ultrasound and MRI. *2013 Radiol Med Oct;*118(7):1119–36
- 41 Iwamoto T, Booser D, Valero V, et al.: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. *J Clin Oncol* 2012;30:729–734

Supplemental Material: Appendix

- 42 Sanford RA, Song J, Gutierrez-Barrera AM et al., High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. *Cancer.* 2015;112:3422–3427
- 43 Deyarmin B et al. Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype. *Ann Surg Oncol* 2013;20:87–93
- 44 Yi M1, Huo L, Koenig KB, et al., Which threshold for ER positivity? A retrospective study based on 9639 patients. *Ann Oncol.* 2014;25:1004–1011
- 45 Rageth CJ, O`Flynn AM, Comstock C et al. First international consensus conference on lesions of uncertain malignant potential in the breast B3 lesions. *Breast Cancer Res Treat* 2016;159:209–213
- 46 Pareja F, Corben AD, Brennan SB et al: Breast intraductal papillomas without atypia in radiologic pathologic concordant core needle biopsies: rate of upgrade to carcinoma at excision. *Cancer* 2016;122:2819–2827
- 47 Sen L, Berh WA, Hooley RJ et al.Core breast biopsies showing lobular carcinoma in situ should be excised and surveillance is reasonable for atypical lobular hyperplasia. *American Journal of Roentgenology* 2016;207:1132–1145
- 48 Brathauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: Previously unexplored aspects assessed in 775 cases and their clinical implications. *Virchows Arch* 2002;440:134–138
- 49 Rageth CJ, O`Flynn AM, Comstock C et al. First international consensus conference on lesions of uncertain malignant potential in the breast (B3 lesions. *Breast Cancer Res Treat* 2016;159:209–213
- 50 American Cancer Society. *Breast Cancer Facts and Figures 2015–2016.* Atlanta: American Cancer Society 2015
- 51 Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. *JAMA Oncol.* 2015;1(7):888–896
- 52 Howlader N, Noone AM, Krapcho M, et al, eds. *SEER Cancer Statistics Review, 1975–2012.* Bethesda, MD: National Cancer Institute. November 2014 SEER data submission. http://seer.cancer.gov/csr/1975_2012/. Accessed September 23, 2015

Supplemental Material: Appendix

- 53 Nadrljanski M, Milosevic Z, Plesinac-Karapandzic V et al. The role of breast magnetic resonance imaging in the diagnosis of ductal carcinoma in situ. *Srp Arh Celok Lek.* 2013;141:402–8
- 54 Fancellu et al. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ *BJS* 2015;102:883–893
- 55 Morrow et al. Society of Surgical Oncology- American Society for Radiation Oncology- American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ *J Clin Onco* 2016;34:4040–4046
- 56 Miller AB, Wall C, Baines C, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: a randomised screening trial *BMJ*. 2014;348:g366
- 57 Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. *J Clin Oncol* 2015;33:3938
- 58 Miller AB, Wall C, Baines C, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: a randomised screening trial *BMJ*. 2014;348:g366
- 59 McCormick B, Winter K, Hudis C, et al. RTOG 9804:a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. *J Clin Oncol* 2015;33:709
- 60 Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. *J Clin Oncol.* 2016 Jul 10;34(20):2341–9
- 61 Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatelian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM,

Supplemental Material: Appendix

- van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med.* 2016 Aug 25;375(8):717–29
- 62 Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). *Eur J Cancer.* 2017 Apr;75:284–298
- 63 Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. *Eur J Cancer.* 2013 May;49(8):1825–35
- 64 Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. *Ann Oncol.* 2016 Aug;27(8):1519–25
- 65 Fasching PA A, Loibl S, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Costa SD, Blohmer JU U, Fehm TN N, Huober J, Liedtke C, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, Wang L, Ingle JN N, Weinshilboum RM M, von Minckwitz G, Couch F. BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study. *SABCS 2015, abstract S5–06*
- 66 Bidard F-C, Michiels S, Mueller V, Riethdorf S, Esserman LJ J, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA A, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo L, Stebbing J, Viens P, Magbanua M, Hall CS S, Engebråtenm O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F-A, Cappelletti MR, Ignatiadis M, Name N, Proudhon C, Wolf D, Bowman Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Gopalkrishna Karhade M, Ruud Mathiesen R, Tokiniwa H, Llombart-Cussac A, D'Hollander K, Cottu P, Park JW W, Loibl S, Pierga J-

Supplemental Material: Appendix

- Y, Pantel K. IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. SABCs 2016, abstract S3–01
- 67 Rastogi P, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol* 2008;26; 778
- 68 Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014;384; 164
- 69 Berruti A, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. *J Clin Oncol* 2014;32; 3883
- 70 Von Minckwitz G, et al "Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)" SABCs 2015;Abstract S2–04
- 71 Sikov WM, Berry DA, Perou CM, et al: Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). *J Clin Oncol*, 2014
- 72 M Untch et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial. *Lancet Oncol* 2016, Published Online, February 8, 2016.
[http://dx.doi.org/10.1016/S1470-2045\(15\)00542-2](http://dx.doi.org/10.1016/S1470-2045(15)00542-2); Gianni L, et al. ETNA ASCO 2016
- 73 Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2012;13; 25–32
- 74 Gianni L et al. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). *J Clin Oncol* 33, 2015 (suppl; abstr 505)

Supplemental Material: Appendix

- 75 Von Minckwitz G, et al. Response-guided neoadjuvant chemotherapy for breast cancer. *J Clin Oncol.* 2013;31; 3623–30
- 76 Ingold Heppner B, et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. *Clin Cancer Res.* 2016 Dec 1;22(23):5747–5754
- 77 Loibl S, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol* 2014;32; 3212
- 78 Loibl S, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. *Clin Cancer Res.* 2016 1;22(11):2675–83
- 79 Loibl S, PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. *Ann Oncol.* 2016;27(8):1519–25
- 80 Spugnesi L, et al. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. *Genes Chromosomes Cancer.* 2016 Dec;55(12):915–924
- 81 Kühn T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. *Lancet Oncol* 2013
- 82 Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. *JAMA* 2013;310; 1455–1461
- 83 Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion. *J Clin Oncol.* 2009 Feb 10;27(5):726–32
- 84 El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection

Supplemental Material: Appendix

- following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016 Nov;212(5):969–981
- 85 Giuliano, J Clin Oncol 2016 (suppl)
- 86 Classe, SABCS, 2016
- 87 Galimberti, Eur J Surg Oncol, 2016
- 88 Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009 Feb 10;27:726–32
- 89 Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802–807
- 90 Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14:609–18
- 91 Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J Clin Oncol. 2015;33:258–264
- 92 Caudle, J Clin Oncol, 2016
- 93 Losken A, Dugal CS, Styblo TM, Carlson GW: A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. Annals of plastic surgery 2014;72:145–149

Supplemental Material: Appendix

- 94 Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. *Ann Surg Oncol.* 2016 Oct;23(10):3190–8
- 95 Berbers J, van Baardwijk A, Houben R, Heuts E, Smidt M, Keymeulen K, Bessems M, Tuinder S, Boersma LJ: 'Reconstruction: Before or after postmastectomy radiotherapy?' A systematic review of the literature. *European journal of cancer* 2014;50:2752–2762
- 96 Kelley BP, Ahmed R, Kidwell KM, Kozlow JH, Chung KC, Momoh AO: A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy: Are current practices ideal? *Ann Surg Oncol* 2014;21:1732–1738
- 97 Waked K, Colle J, Doornaert M, Cocquyt V, Blondeel P. Systematic review: The oncological safety of adipose fat transfer after breast cancer surgery. *Breast*. 2016 Nov 9;31:128–136
- 98 Macadam SA, Zhong T, Weichman K, Papsdorf M, Lennox PA, Hazen A, Matros E, Disa J, Mehrara B, Pusic AL. Quality of Life and Patient-Reported Outcomes in Breast Cancer Survivors: A Multicenter Comparison of Four Abdominally Based Autologous Reconstruction Methods.) *Plast Reconstr Surg.* 2016 Mar;137(3):758–71
- 99 Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2014 Aug;190705–14
- 100 Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Fussl C, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). *Strahlenther Onkol.* 2014 Apr;190342–51
- 101 Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol.* 2013 Oct;14:1086–94

Supplemental Material: Appendix

- 102 Coates AS¹, Winer EP², Goldhirsch A³, Gelber RD⁴, Gnant M⁵, Piccart-Gebhart M⁶, Thürlimann B⁷, Senn HJ⁸; Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26:1533–46
- 103 Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:A Brief Summary of the Consensus Discussion. Breast Care (Basel). 2015 Apr;10:124–30
- 104 Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A, Taghian AG, Vicini FA, White JR, Haffty BG. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81:59–68
- 105 Harris JR. Critical Decision-Making in Radiation Therapy for Breast Cancer. Presentation at the San Antonio Breast Cancer Symposium 2015. Cancer Res February 15, 2016 76:PL1–01
- 106 Harris JR. Critical Decision-Making in Radiation Therapy for Breast Cancer. Presentation at the San Antonio Breast Cancer Symposium 2015. Cancer Res February 15, 2016 76:PL1–01
- 107 Yarnold J. Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-genomic issues. Breast 2015;24(Suppl 1): PG 10.01
- 108 Whelan T. Tailoring or omitting radiotherapy in early breast cancer. Cancer Res February 15, 2016 76:ES6–2
- 109 Bartelink H, Maingon P, Poortmans P, et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan;16:47–56
- 110 Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31:2382–7

Supplemental Material: Appendix

- 111 EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet.* 2014 Jun 21;383[9935]:2127–35
- 112 Kyndi et al. 2013
- 113 Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumours and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. *Int J Radiat Oncol Biol Phys.* 2005 Apr 1;61:1337–47
- 114 Shen H, Zhao L, Wang L, Liu X, Liu X, Liu J, Niu F, Lv S, Niu Y. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumour and 1–3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases. *Tumour Biol.* 2015 Dec 2
- 115 Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. *Radiother Oncol.* 2009 Jan;90:74–9
- 116 Poortmans PM, Collette S, Kirkove C, et al.; EORTC Radiation Oncology and Breast Cancer Groups. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. *N Engl J Med.* 2015 Jul 23;373:317–27
- 117 Whelan TJ, Olivotto IA, Parulekar WR, et al.; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. *N Engl J Med.* 2015 Jul 23;373:307–16
- 118 Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. *J Clin Oncol.* 2016 Feb 1;34:314–20
- 119 Budach W, Bölk E, Kammer K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized trials- an update. *Radiat Oncol.* 2015 Dec 21;10:258

Supplemental Material: Appendix

- 120 Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013;381:805–816
- 121 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. *J Natl Cancer Inst* 2005;97:1262–1271
- 122 Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al.: Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2015;372:436–446
- 123 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al.: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 2015;386:1341–1352
- 124 Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J: Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – meta-analyses on efficacy and adverse events based on randomized clinical trials. *Breast* 2016;26:106–114
- 125 Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013;381:805–816; 2
- 126 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. *J Natl Cancer Inst* 2005;97:1262–1271
- 127 Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al.: Extending Aromatase-inhibitor adjuvant therapy to 10 years. *N Engl J Med* 2016;375:209–219
- 128 Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, et al.: Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for

Supplemental Material: Appendix

- hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol 2016;27:806–812
- 129 Jacobs SA, Wilson JW, Bandos H, al. e: NSABP B-36:Randomized phase III trial comparing 6 cycles of 5-FU, epirubicin, and cyclophosphamide (FEC) to 4 cycles of ac in node-negative breast cancer: SABCS. San Antonio, 2014
- 130 Sparano JA, Zhao F, Martino S, Ligibel J, Saphner T, Wolff AC, Sledge GW, Perez EA, Wood WC, Davidson NE: Ten year update of e1199:Phase iii study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: SABCS. San Antonio, 2014
- 131 Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus cmf as adjuvant chemotherapy for older women with early breast cancer: Final results of the randomized phase iii elda trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015;26:675–682
- 132 Shulman LN, Berry DA, Cirrincione CT, et al., Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311–2317
- 133 Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al., 2 years versus 1 year of adjuvant trastuzumab for her2-positive breast cancer (hera): An open-label, randomised controlled trial. Lancet 2013;382:1021–1028
- 134 Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with her2-positive early breast cancer (phare): A randomised phase 3 trial. Lancet oncology 2013;14:741–748
- 135 Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England Jjournal of Medicine 2015;372:134–141
- 136 Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC1, Viale G1, Zujewski JA1, Goldhirsch A1, Armour A1, Pritchard KI1, McCullough AE1, Dolci S1, McFadden E1, Holmes AP1, Tonghua L1, Eidtmann H1, Dinh P1, Di Cosimo S1, Harbeck N1, Tjulandin S1, Im YH1, Huang CS1, Diéras V1, Hillman DW1, Wolff AC1,

Supplemental Material: Appendix

- Jackisch C1, Lang I1, Untch M1, Smith I1, Boyle F1, Xu B1, Gomez H1, Suter T1, Gelber RD1, Perez EA1. Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. *J Clin Oncol.* 2016 Apr 1;34(10):1034–42
- 137Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz B, Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E: Tibolone increases bone mineral density but also relapse in breast cancer survivors: Liberate trial bone substudy. *Breast cancer research : BCR* 2012;14:R13
- 138Buchholz S, Mogele M, Lintermans A, Bellen G, Prasauskas V, Ortmann O, Grob P, Neven P, Donders G: Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. *Climacteric : the journal of the International Menopause Society* 2015;18:252–259
- 139Loibl S, Lintermans A, Dieudonne AS, Neven P: Management of menopausal symptoms in breast cancer patients. *Maturitas* 2011;68:148–154
- 140Roberts H: Safety of herbal medicinal products in women with breast cancer. *Maturitas* 2010;66:363–369
- 141Pruthi S, Qin R, Terstreich SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL: A phase iii, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North central cancer treatment group n08c7. *Menopause* 2012;19:48–53
- 142Leach MJ, Moore V: Black cohosh (*cimicifuga spp.*) for menopausal symptoms. *Cochrane Database Syst Rev* 2012;9:Cd007244
- 143Caraci F, Crupi R, Drago F, Spina E: Metabolic drug interactions between antidepressants and anticancer drugs: Focus on selective serotonin reuptake inhibitors and hypericum extract. *Current drug metabolism* 2011;12:570–577
- 144Kim MS, Lim HJ, Yang HJ, Lee MS, Shin BC, Ernst E: Ginseng for managing menopause symptoms: A systematic review of randomized clinical trials. *Journal of ginseng research* 2013;37:30–36
- 145Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, Kennedy D, Cooley K, Wong R, Sagar S, Sabri E, Fergusson D. Soy, red clover, and isoflavones and breast cancer: a systematic review. *PLoS One.* 2013 Nov 28;8e81968

Supplemental Material: Appendix

- 146 Ghazanfarpour M, Sadeghi R, Latifnejad Roudsari R, Mirzaii Najmabadi K, Mousavi Bazaz M, Abdolahian S, Khadivzadeh T. Effects of red clover on hot flash and circulating hormone concentrations in menopausal women: a systematic review and meta-analysis. *Avicenna J Phytomed.* 2015 Nov-Dec;5498–511
- 147 Mann E: Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. *Lancet Oncol.* 2012 Mar;13309–18
- 148 Buffart LM: Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer.* 2012 Nov 27;12:559; Cramer H: Characteristics of randomized controlled trials of yoga: a bibliometric analysis. *BMC Complement Altern Med.* 2014 Sep 2;14:328
- 149 Moore HC, Unger JM, Phillips KA, et al., Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *The New England journal of medicine* 2015;372:923–932
- 150 Committee opinion no. 618:Ovarian reserve testing. *Obstetrics and gynecology* 2015;125:268–273
- 151 Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S: Caring for the breast cancer survivor's health and well-being. *World journal of clinical oncology* 2014;5:693–704
- 152 Hatzichristou D, Rosen RC, Denogatis LR, Low WY, Sadovsky R, Symonds T. Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med* 2010;7:337–348
- 153 Quinlan-Woodward J, Gode A, Dusek JA: Assessing the Impact of Acupuncture on Pain, Nausea, Anxiety, and Coping in Women Undergoing a Mastectomy. *Oncol Nurs Forum.* 2016 Nov 1;43(6):725–732
- 154 Simapivapan P, Boltong A, Hodge A. To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. *Cancer Treat Rev.* 2016 Nov;50:155–167. doi: 10.1016/j.ctrv.2016.09.010
- 155 Dieli-Conwright CM, Lee K, Kiwata JL: Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise. *Curr Breast Cancer Rep.* 2016;8(3):139–150

Supplemental Material: Appendix

- 156 Lengacher CA, Reich RR, Paterson CL: Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *J Clin Oncol.* 2016 Aug 20;34(24):2827–34
- 157 Cramer H, Lauche R, Klose P: Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database Syst Rev.* 2017 Jan 3;1:CD010802
- 158 Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, Friedman E, Gelmon K, Gentilini O, Geraghty J, Harbeck N, Higgins S, Loibl S, Moser E, Peccatori F, Raanani H, Kaufman B, Cardoso F: Second international consensus guidelines for breast cancer in young women (BCY2). *Breast* 2016;26:87–99
- 159 Lambertini M, Falcone T, Unger JM, Phillips KA, Del Mastro L, Moore HC: Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer. *J Clin Oncol* 2016;JCO2016692582
- 160 Guth U, Huang DJ, Bitzer J, Tirri BF, Moffat R: Contraception counseling for young breast cancer patients: A practical needs assessment and a survey among medical oncologists. *Breast* 2016;30:217–221
- 161 Fehm T, Souchon R: Axilläre Lymphknotenmetastasen bei CUP. *Onkologe* 2013;19:40–43
- 162 Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB: Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. *Histopathology* 2016;68:367–377
- 163 Xu Q, Chen J, Ni S, Tan C, Xu M, Dong L, Yuan L, Wang Q, Du X: Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin. *Mod Pathol* 2016;29:546–556
- 164 Moran S, Martinez-Cardus A, Sayols S, Musulen E, Balana C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miro M, Matias-Guiu X, Pazo-Cid R, Anton A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Milesikin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M: Epigenetic profiling to classify

Supplemental Material: Appendix

- cancer of unknown primary: A multicentre, retrospective analysis. *Lancet Oncol* 2016;17:1386–1395
- 165 Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ: Comprehensive genomic profiling of carcinoma of unknown primary site: New routes to targeted therapies. *JAMA Oncol* 2015;1:40–49
- 166 Pawaskar AS, Basu S: Role of 2-fluoro-2-deoxyglucose pet/computed tomography in carcinoma of unknown primary. *PET Clin* 2015;10:297–310
- 167 Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, Yepes MM, Lippman ME: Paget's disease of the nipple. *Breast Cancer Res Treat* 2013;141:1–12
- 168 Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH: Phyllodes tumours of the breast: A consensus review. *Histopathology* 2016;68:5–21
- 169 Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH, Phyllodes Tumour Network S: Predicting clinical behaviour of breast phyllodes tumours: A nomogram based on histological criteria and surgical margins. *J Clin Pathol* 2012;65:69–76
- 170 Kim YJ, Kim K: Radiation therapy for malignant phyllodes tumor of the breast: An analysis of seer data. *Breast* 2016;32:26–32
- 171 Zeng S, Zhang X, Yang D, Wang X, Ren G: Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. *Mol Clin Oncol* 2015;3:663–671
- 172 Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA: Utilization of radiotherapy for malignant phyllodes tumors: Analysis of the national cancer data base, 1998–2009. *Ann Surg Oncol* 2014;21:1222–1230
- 173 Ghareeb ER, Bhargava R, Vargo JA, Florea AV, Beriwal S: Primary and radiation-induced breast angiosarcoma: Clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. *Am J Clin Oncol* 2016;39:463–467

Supplemental Material: Appendix

- 174 Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P: Surgical management of radiation-induced angiosarcoma after breast conservation therapy. *Am J Surg* 2012;203:156–161
- 175 Shah S, Rosa M: Radiation-associated angiosarcoma of the breast: Clinical and pathologic features. *Arch Pathol Lab Med* 2016;140:477–481
- 176 Ramos-Gallardo G, Cuenca-Pardo J, Rodriguez-Olivares E, Iribarren-Moreno R, Contreras-Bulnes L, Vallarta-Rodriguez A, Kalixto-Sanchez M, Hernandez C, Ceja-Martinez R, Torres-Rivero C: Breast implant and anaplastic large cell lymphoma meta-analysis. *J Invest Surg* 2017;30:56–65
- 177 Clemens MW, Horwitz SM: NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J* 2017 (Epub ahead of print)